ArticleHeliyon2025
Assessing the visibility and public engagement of bone marrow and stem cell transplantation research: An altmetric analysis.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global trends and mechanistic insights into A20 (TNFAIP3) in autoimmunity and inflammation.American journal of translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bone marrow and stem cell transplantation have led to significant advancements in modern medicine, offering potential cures for various hematological disorders and specific cancers. This study aims to investigate and analyze research in this field using altmetrics in a world outside the academic scholarly and publishing environment. Methods: This study examines articles in the field of bone marrow and stem cell transplantation in a ten-year period (2013-2022) extracted from the Web of Science database. The Altmetric Explorer database and tool were used to extract data. After an initial review of the data for their completeness and accuracy, the study considered descriptive reports, statistical analyses, bibliometric network analysis, and overlaps between articles, journals, and research centers in terms of the Altmetric Attention Score (AAS) and citations using Excel, SPSS, Python, R, and VOSviewer. Result: This study evaluated 12924 articles published in 293 journals. Findings show that 85.67% of the articles were mentioned at least once on various social media and their tools. The AAS varied between 0 and 1125, and the median of this score was 2. The highest score was assigned to an article that provides critical insights into the outcomes of patients with refractory diffuse large B-cell lymphoma (DLBCL). Mendeley, X (formerly Twitter), and News were the most important and active social tools, respectively, where these articles were mentioned. The highest number of tweets, news stories, Facebook posts, and policy documents were from the USA, USA, USA, and UK, respectively. The @PaperbirdsM and @MayoClinic accounts on X had the highest tweet and follower statistics, respectively. The University of Texas MD Anderson Cancer Center also had the highest number of mentions on social networks. Network analysis maps of the top AAS articles showed "Stem Cell Transplantation" as the most popular author keyword, with Conclusion: A high percentage of articles in this field are present on social networks and platforms. Furthermore, highly cited articles on social media have attracted more attention. Both traditional and web-based metrics offer different perspectives on scholarly impact. While each provides valuable insights, further research is needed to explore how these metrics can be effectively combined for a more comprehensive evaluation of scientific outputs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.